CLARITY IBD

NIHR portfolio adopted study exploring the impaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTy in IBD.

[CLARITY IBD @clarityibd]

A BIG day for CLARITY IBD

1. The latest video has been released
https://t.co/Z3g3ytJdmG

2. Data has been presented at #ECCO2022 👏👏 @SimengLin

3. @clarityibd research teams across the UK have been working hard updating data so we can release the next publication 👏👏🙏🙏

[CLARITY IBD @clarityibd]

@ZhigangLiu66 @LancetGastroHep Great work @ZhigangLiu66

[Zhigang Liu @ZhigangLiu66]

We are glad to share that our latest manuscript from the CLARITY IBD study is now published in
@LancetGastroHep. Thank you to all @clarityibd contributors, patients, and collaborators!

[CLARITY IBD @clarityibd]

@BoytonRosemary @Daltmann10 @RoyalDevonNHS

[CLARITY IBD @clarityibd]

New @clarityibd findings 👇
❗to continue SARS-CoV-2 vaccination programmes, inc. second-generation bivalent vaccines. Esp when vaccine immunogenicity and efficacy might be reduced, such as those on anti-TNF therapies.
Great work, thank you 👏👏👏
#ibdpatients @NIHRtakepart

[CLARITY IBD @clarityibd]

@LancetGastroHep @NickPowellLab @nikki_k1 @ibdseb @tariqahmadIBD @JamesGoodhand1 @SimengLin @nchanchlani1 @rachelnice3 @T_J_McDonald @DrChrisLamb @RichardPollok @charlie_lees

[CLARITY IBD @clarityibd]

New @clarityibd findings 👇
❗to continue SARS-CoV-2 vaccination programmes, inc. second-generation bivalent vaccines. Esp when vaccine immunogenicity and efficacy might be reduced, such as those on anti-TNF therapies.
Great work, thank you 👏👏👏
#ibdpatients @NIHRtakepart

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New research - Liu et al - Neutralising antibody potency against SARS-CoV-2 wild-type & omicron BA.1 & BA.4/5 variants in patients with #IBD treated with infliximab & vedolizumab after 3 doses of #COVID19 vaccine

@clarityibd

https://t.co/mhF3axLtN0

#gitwitter #idtwitter

[VIP Study @VIPStudy1]

👀More data from @VIPStudy1

Main message for #IBDpatients -
✔️ get NEW boosters = protection against Omicron variants.

New boosters especially ☑️☑️ for those on anti -TNF and tofacitinib drugs.

#COVID19Ab
#IBD
@AGA_Gastro
@NickPowellLab

https://t.co/IXhWUmaTUt

[VIP Study @VIPStudy1]

👀More data from @VIPStudy1

Main message for #IBDpatients -
✔️ get NEW boosters = protection against Omicron variants.

New boosters especially ☑️☑️ for those on anti -TNF and tofacitinib drugs.

#COVID19Ab
#IBD
@AGA_Gastro
@NickPowellLab

[CLARITY IBD @clarityibd]

@victhesmith @UKCovidVaxHub @Daltmann10 @BoytonRosemary @tariqahmadIBD @JamesGoodhand1 @DrAilsaHart @Merlin_Davies @nchanchlani1 @SimengLin @ClaireBewshea Thanks for your question, we will get a response to you over the next few days.

[UK Covid Vaccine Research Hub @UKCovidVaxHub]

Drug commonly used to treat inflammatory bowel disease limits protection given by 3rd #COVID #vaccine dose, finds new study from @clarityibd

People on Infliximab were more than twice as likely to get a breakthrough infection.

Read the full story
👇
https://t.co/itdygefhiw

[Claire Bewshea @ClaireBewshea]

👀If you haven’t seen it yet - the latest results from @clarityibd are summarised 👇

Thank you 🙏 to all 7000 patients and 92 research sites - this wouldn’t happen without YOU 👍

#Collaboration #ibdpatients #ibdresearch #COVID19 @Gut_BMJ

[Simeng Lin @SimengLin]

Results from the latest @clarityibd paper published in @Gut_BMJ summarised here:

[Charlie Lees @charlie_lees]

Withdrawal of @BritSocGastro IBD risk grid for COVID severity @Gut_BMJ

• reassuring for patients, with
• vaccines, boosters and antivirals

"We predict that the disruption from the pandemic for individuals with IBD will largely be no different to the general population."

[Jonathan Segal @Jonathansegal85]

Brilliant study led by @philip_j_smith just out in #JCC exploring switching from IV to s/c IFX. Well done team.

https://t.co/kkwMJoVotu

[Simeng Lin @SimengLin]

@tariqahmadIBD @DrNickKennedy @JamesGoodhand1 @NickPowellLab @charlie_lees @ibdseb @aamirs28 @nchanchlani1 @ClaireBewshea We are pleased to share our latest manuscript from the CLARITY IBD study is now published in @NatureComms

Thank you to all our @clarityibd contributors, patients, and collaborators.

https://t.co/iVnoPEt8Fl

[CLARITY IBD @clarityibd]

Wow, thank you @EmmaHHFT and Team @HHFTResearch @HHFTnhs. Your contribution and hard work to @clarityibd has been invaluable.

[CLARITY IBD @clarityibd]

@RDEResearch @RDEhospitals @ExeterNihr @ExeterMed

[CLARITY IBD @clarityibd]

Dr Tariq Ahmad @tariqahmadIBD discussing @clarityibd. How enabling research during the covid era, could change the way we do research in the future.
#patientledresearch #electronicconsent #collaboration

[CLARITY IBD @clarityibd]

Dr Tariq Ahmad @tariqahmadIBD discussing @clarityibd. How enabling research during the covid era, could change the way we do research in the future.
#patientledresearch #electronicconsent #collaboration

[CLARITY IBD @clarityibd]

Dr Tariq Ahmad @tariqahmadIBD discussing @clarityibd. How enabling research during the covid era, could change the way we do research in the future.
#patientledresearch #electronicconsent #collaboration

[James Goodhand @JamesGoodhand1]

Case study: CLARITY IBD: Changing the way we do research | NIHR https://t.co/fnRtFuhNLj

[James Goodhand @JamesGoodhand1]

Case study: CLARITY IBD: Changing the way we do research | NIHR https://t.co/fnRtFuhNLj